Nothing Special   »   [go: up one dir, main page]

GB201120259D0 - Allogeneic immune response control - Google Patents

Allogeneic immune response control

Info

Publication number
GB201120259D0
GB201120259D0 GBGB1120259.5A GB201120259A GB201120259D0 GB 201120259 D0 GB201120259 D0 GB 201120259D0 GB 201120259 A GB201120259 A GB 201120259A GB 201120259 D0 GB201120259 D0 GB 201120259D0
Authority
GB
United Kingdom
Prior art keywords
immune response
response control
allogeneic immune
rejection
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1120259.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Academisch Medisch Centrum
Original Assignee
Universiteit Gent
Academisch Medisch Centrum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Academisch Medisch Centrum filed Critical Universiteit Gent
Priority to GBGB1120259.5A priority Critical patent/GB201120259D0/en
Publication of GB201120259D0 publication Critical patent/GB201120259D0/en
Priority to PCT/EP2012/073466 priority patent/WO2013076245A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates in general to prevention, reduction or treatment of rejection in transplant patients. In particular the invention relates to the use of SSRIs (selective serotonin reuptake inhibitors) for the prevention, reduction or treatment of rejection in transplant patients, such as blood cell, stem cell, bone marrow, tissue or organ rejection.
GBGB1120259.5A 2011-11-24 2011-11-24 Allogeneic immune response control Ceased GB201120259D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1120259.5A GB201120259D0 (en) 2011-11-24 2011-11-24 Allogeneic immune response control
PCT/EP2012/073466 WO2013076245A1 (en) 2011-11-24 2012-11-23 Allogeneic immune response control

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1120259.5A GB201120259D0 (en) 2011-11-24 2011-11-24 Allogeneic immune response control

Publications (1)

Publication Number Publication Date
GB201120259D0 true GB201120259D0 (en) 2012-01-04

Family

ID=45475635

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1120259.5A Ceased GB201120259D0 (en) 2011-11-24 2011-11-24 Allogeneic immune response control

Country Status (2)

Country Link
GB (1) GB201120259D0 (en)
WO (1) WO2013076245A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3324952B1 (en) 2015-07-17 2020-12-16 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658955A (en) 1994-11-01 1997-08-19 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of immune disorders
WO2008118423A1 (en) * 2007-03-26 2008-10-02 Combinatorx, Incorporated Compositions and methods for treating medical conditions
US20100081713A1 (en) * 2008-03-19 2010-04-01 CombinatoRx, (Singapore) Pte. Ltd. Compositions and methods for treating viral infections

Also Published As

Publication number Publication date
WO2013076245A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
PH12018501264A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
MX359769B (en) Methods of decellularizing bone.
MX2019001414A (en) Angiogenesis using placental stem cells.
IN2014DN08676A (en)
IL229284A0 (en) Sterilized, acellular extracellular matrix compositions and methods of making thereof
MX2010005018A (en) Treatment of premature birth complications.
MX2019012154A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases.
MX2012011543A (en) Treatment of sarcoidosis using placental stem cells.
UA106403C2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
SG185638A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
IN2014MN01981A (en)
MY158992A (en) Forms of rifaximin and uses thereof
MX2013004061A (en) Cyclosporin analogs.
MX354988B (en) Antibody formulations and methods.
MX2013006595A (en) Treatment of spinal cord injury and traumatic brain injury using placental stem cells.
EA201390010A1 (en) SUBSTITUTED TRIAZOLOPIRIDINES
MX2016004556A (en) Compressed bone composition and methods of use thereof.
MX356755B (en) Fumigillol type compounds and methods of making and using same.
WO2012047951A3 (en) Human lung stem cells and uses thereof
IN2015KN00201A (en)
MX2013004062A (en) Cyclosporin analogs.
MY157534A (en) Composition for skin external application and functional food containing rose placenta tissue culture or extract thereof
MX2014000567A (en) Treatment of radiation injury using amnion derived adherent cells.
GEP20197052B (en) Hyr1-derived compositions and methods of treatment using same

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)